Cullinan Therapeutics, Inc. 8-K Filing
Ticker: CGEM · Form: 8-K · Filed: Nov 21, 2025 · CIK: 1789972
| Field | Detail |
|---|---|
| Company | Cullinan Therapeutics, Inc. (CGEM) |
| Form Type | 8-K |
| Filed Date | Nov 21, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Cullinan Therapeutics, Inc. (ticker: CGEM) to the SEC on Nov 21, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.0001 (nge on which registered Common Stock, $0.0001 par value per share CGEM The Nasdaq).
How long is this filing?
Cullinan Therapeutics, Inc.'s 8-K filing is 2 pages with approximately 471 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 471 words · 2 min read · ~2 pages · Grade level 13.3 · Accepted 2025-11-21 16:30:26
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share CGEM The Nasdaq
Filing Documents
- cgem-20251118.htm (8-K) — 39KB
- 0001193125-25-291448.txt ( ) — 142KB
- cgem-20251118.xsd (EX-101.SCH) — 24KB
- cgem-20251118_htm.xml (XML) — 5KB
02 Termination of a Material Definitive Agreement
Item 1.02 Termination of a Material Definitive Agreement. On November 18, 2025, in connection with its decision not to pursue further development of CLN-617, Cullinan Amber Corp. (the "Company"), a subsidiary of Cullinan Therapeutics, Inc. notified Massachusetts Institute of Technology ("MIT") of its decision to terminate the Exclusive Patent License Agreement, dated December 20, 2019 between the Company and MIT, as amended from time to time (the "License Agreement"), effective as of February 18, 2026. Pursuant to the License Agreement, MIT had granted the Company exclusive worldwide rights to the technology underlying CLN-617 to develop a cancer immunotherapy product worldwide. In connection with the termination of the License Agreement, the Company will return the licensed patent rights for the technology underlying CLN-617 to MIT.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CULLINAN THERAPEUTICS, INC. Date: November 21, 2025 By: /s/ Mary Kay Fenton Mary Kay Fenton Chief Financial Officer